About this item:

583 Views | 428 Downloads

Author Notes:

Corresponding author: Guillermo E. Umpierrez, geumpie@emory.edu.

G.E.U. initiated and designed the study and wrote the initial research proposal and manuscript. R.G. initiated and designed the study, reviewed and edited the research proposal and manuscript, and contributed to the discussion. D.S., S.J., D.H.W., C.N., F.F., and L.P. reviewed and edited the research proposal and manuscript and contributed to the discussion. D.R. and S.L.-P. collected the research data.

F.P. reviewed and edited the research proposal and manuscript, contributed to the discussion, and collected the research data. G.E.U. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This investigator-initiated study was supported by an unrestricted grant from Merck. No other potential conflicts of interest relevant to this article were reported.


Research Funding:

G.E.U. is supported in part by research grants from the American Diabetes Association (7-03-CR-35) and PHS Grant UL1-RR-025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources.

The sponsors of this study were not involved in the study design, data collection, analysis or interpretation of the results, or preparation of the manuscript.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Endocrinology & Metabolism

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized, controlled study

Show all authors Show less authors


Journal Title:

Diabetes Care


Volume 36, Number 11


, Pages 3430-3435

Type of Work:

Article | Final Publisher PDF


OBJECTIVE-This study investigated the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients. RESEARCHDESIGNANDMETHODSdIn this pilot, multicenter, open-label, randomized study, patients (n = 90) with a known history of T2D treated with diet, oral antidiabetic agents, or low total daily dose of insulin (#0.4 units/kg/day) were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro. Major study outcomes included differences in daily blood glucose (BG), frequency of treatment failures (defined as three or more consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL), and hypoglycemia between groups. RESULTS-Glycemic control improved similarly in all treatment groups. There were no differences in the mean daily BG after the 1st day of treatment (P = 0.23), number of readings within a BG target of 70 and 140 mg/dL (P = 0.53), number of BG readings >200 mg/dL (P = 0.23), and number of treatment failures (P > 0.99). The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P < 0.001). There were no differences in length of hospital stay (P = 0.78) or in the number of hypoglycemic events between groups (P = 0.86). CONCLUSIONS-Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D. © 2013 by the American Diabetes Association.

Copyright information:

© 2013 by the American Diabetes Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License ( http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits distribution, public display, and publicly performance, making multiple copies, provided the original work is properly cited. This license requires copyright and license notices be kept intact, credit be given to copyright holder and/or author. This license prohibits exercising rights for commercial purposes.

Creative Commons License

Export to EndNote